The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022 — Michel Ducreux (2023) | RDL Network
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
ESMO Open 8(3): 101567-101567
Article 2023 English
Authors
MD
Michel Ducreux
GA
Ghassan K. Abou‐Alfa
TB
Tanios Bekaii‐Saab
Abstract
1 min read
This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.
Masatoshi Kudo, Kwang–Hyub Han, S.-L. Ye, Jianhua Zhou, Yi‐Hsiang Huang, Shi‐Ming Lin, Chien‐Kuo Wang, Masafumi Ikeda, Stephen L. Chan, Su Pin Choo, Shiro Miyayama, Ann‐Lii Cheng, On Behalf Of The APPLE Association
Amit G. Singal, Marco Sanduzzi‐Zamparelli, Pierre Nahon, Maxime Ronot, Yujin Hoshida, Nicole E. Rich, María Reig, Valérie Vilgrain, Jorge A. Marrero, Josep M. Llovet, Neehar D. Parikh, Augusto Villanueva
Discussion(0)
No comments yet. Be the first to comment.